Noroplex (Dimethyl Fumarate)

Dimethyl fumarate, the active ingredient in Noroplex, is a fumaric acid ester presented as an unknown strength/unknown form for oral use. It treats multiple sclerosis and plaque psoriasis in adult patients.

GNH USA supplies Noroplex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noroplex is used in conditions where modulation of the immune response via the Nrf2 pathway is beneficial.

Multiple sclerosis: reduces relapse frequency and slows disability progression in adults. Plaque psoriasis: improves skin lesions and decreases disease severity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Flushing: transient warmth and redness, often on the face. - Gastrointestinal upset: nausea, abdominal pain, or diarrhoea. - Lymphopenia: reduced white‑blood‑cell count, usually mild. - Headache: mild to moderate intensity.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare opportunistic brain infection. - Severe liver injury: elevated transaminases or hepatitis. - Anaphylaxis or severe allergic reactions: swelling, difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

Patients should be monitored for safety concerns before and during therapy. - Lymphocyte monitoring: check counts regularly to detect lymphopenia. - Liver function: assess baseline enzymes and repeat as needed. - Infection risk: avoid initiating therapy in active infections. - Renal impairment: use with caution in reduced kidney function. - Pregnancy and lactation: safety not established; discuss risks with a healthcare professional. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Dimethyl fumarate may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Immunosuppressants (e.g., azathioprine, methotrexate): may increase infection risk. - Live vaccines: reduced vaccine efficacy and potential disease. - Strong CYP inducers (e.g., rifampicin): may lower dimethyl fumarate exposure.

Moderate Interactions (Monitor Closely):\n- Statins: possible additive liver enzyme elevation. - Antihypertensives: monitor blood pressure changes. - Oral contraceptives: may alter hormonal levels. - Antacids: could affect gastrointestinal tolerance.